Citations (26)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Chengjuan Chen, Dianxiang Lu, Tao Sun & Tiantai Zhang. (2022) JAK3 inhibitors for the treatment of inflammatory and autoimmune diseases: a patent review (2016–present). Expert Opinion on Therapeutic Patents 32:3, pages 225-242.
Read now
Read now
Lauren M. Mathias & William Stohl. (2020) Systemic lupus erythematosus (SLE): emerging therapeutic targets. Expert Opinion on Therapeutic Targets 24:12, pages 1283-1302.
Read now
Read now
Articles from other publishers (24)
Evgeniya A. Shatokhina, Aleksandra S. Polonskaia, Anastasiya Yu. Syryseva, Anna V. Michenko, Maksim N. Shatokhin & Larisa S. Kruglova. (2023) Janus kinase inhibitors efficacy for the treatment of adult atopic dermatitis in real clinical practice. Russian Journal of Allergy 20:2, pages 238-249.
Crossref
Crossref
Yuh Cai Chia, Mat Jusoh Siti Asmaa, Marini Ramli, Peng Yeong Woon, Muhammad Farid Johan, Rosline Hassan & Md Asiful Islam. (2023) Molecular Genetics of Thrombotic Myeloproliferative Neoplasms: Implications in Precision Oncology. Diagnostics 13:1, pages 163.
Crossref
Crossref
Chengjuan Chen, Yuan YinGaona ShiYu ZhouShuai Shao, Yazi WeiLei WuDayong ZhangLan Sun & Tiantai Zhang. (2022) A highly selective JAK3 inhibitor is developed for treating rheumatoid arthritis by suppressing γc cytokine–related JAK-STAT signal. Science Advances 8:33.
Crossref
Crossref
Henry G Kaplan, Ruyun Jin, Carlo B Bifulco, James M Scanlan & David R Corwin. (2022)
PCM1-JAK2
Fusion Tyrosine Kinase Gene-Related Neoplasia: A Systematic Review of the Clinical Literature
. The Oncologist 27:8, pages e661-e670.
Crossref
Crossref
Yuh Cai Chia, Marini Ramli, Peng Yeong Woon, Muhammad Farid Johan, Rosline Hassan & Md Asiful Islam. (2021) Molecular genetics of thrombotic myeloproliferative neoplasms: Implications in precision oncology. Genes & Diseases.
Crossref
Crossref
Caroline Lo Presti, Florence Fauvelle, Julie Mondet & Pascal Mossuz. (2020) The differential activation of metabolic pathways in leukemic cells depending on their genotype and micro-environmental stress. Metabolomics 16:1.
Crossref
Crossref
Min Hu, Chengbo Xu, Chao Yang, Hongli Zuo, Chengjuan Chen, Dan Zhang, Gaona Shi, Wenjie Wang, Jiangong Shi & Tiantai Zhang. (2019) Discovery and evaluation of ZT55, a novel highly-selective tyrosine kinase inhibitor of JAK2V617F against myeloproliferative neoplasms. Journal of Experimental & Clinical Cancer Research 38:1.
Crossref
Crossref
Yvan Jamilloux, Thomas El Jammal, Lucine Vuitton, Mathieu Gerfaud-Valentin, Sébastien Kerever & Pascal Sève. (2019) JAK inhibitors for the treatment of autoimmune and inflammatory diseases. Autoimmunity Reviews 18:11, pages 102390.
Crossref
Crossref
Massimo Gadina, Catrina Johnson, Daniella Schwartz, Michael Bonelli, Sarfaraz Hasni, Yuka Kanno, Paul Changelian, Arian Laurence & John J O’Shea. (2018) Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology 104:3, pages 499-514.
Crossref
Crossref
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni & Daniella M. Schwartz. (2017) JAK–STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs 77:5, pages 521-546.
Crossref
Crossref
L. C. Macedo, B. C. Santos, S. Pagliarini‐e‐Silva, K. B. B. Pagnano, C. Rodrigues, F. C. Quintero, M. E. Ferreira, E. C. Baraldi, E. P. Ambrosio‐Albuquerque, A. M. Sell & J. E. L. Visentainer. (2015)
JAK2 46/1 haplotype is associated with
JAK
2 V617F – positive myeloproliferative neoplasms in Brazilian patients
. International Journal of Laboratory Hematology 37:5, pages 654-660.
Crossref
Crossref
Youwen Qin, Xiaorui Wang, Chuxian Zhao, Chun Wang & Yining Yang. (2015) The impact of JAK2V617F mutation on different types of thrombosis risk in patients with essential thrombocythemia: a meta-analysis. International Journal of Hematology 102:2, pages 170-180.
Crossref
Crossref
Marco Benati, Martina Montagnana, Elisa Danese, Giovanna De Matteis, Dino Veneri, Elisa Paviati & Gian Cesare Guidi. (2015) Role of JAK2 V617F mutation and aberrant expression of microRNA-143 in myeloproliferative neoplasms. Clinical Chemistry and Laboratory Medicine (CCLM) 53:7.
Crossref
Crossref
T.P. Santisakultarm, C.Q. Paduano, T. Stokol, T.L. Southard, N. Nishimura, R.C. Skoda, W.L. Olbricht, A.I. Schafer, R.T. Silver & C.B. Schaffer. (2014) Stalled cerebral capillary blood flow in mouse models of essential thrombocythemia and polycythemia vera revealed by in vivo two‐photon imaging. Journal of Thrombosis and Haemostasis 12:12, pages 2120-2130.
Crossref
Crossref
Güven Cetin, Tuba Ozkan, Seda Turgut, M. Ali Cikrikcioglu, M. Cem Ar, Mesut Ayer, Ayhan Unlu, Sevda Rabia Celik, Yahya Sekin & Cumali Karatoprak. (2014) Evaluation of clinical and laboratory findings with JAK2 V617F mutation as an independent variable in essential thrombocytosis. Molecular Biology Reports 41:10, pages 6737-6742.
Crossref
Crossref
Francesco Dentali, Walter Ageno, Elisa Rumi, Ilaria Casetti, Daniela Poli, Umberto Scoditti, Margherita Maffioli, Matteo Nicola Dario di Minno, Domenica Caramazza, Daniela Pietra, Valerio De Stefano & Francesco Passamonti. (2014) Cerebral venous thrombosis and myeloproliferative neoplasms: Results from two large databases. Thrombosis Research 134:1, pages 41-43.
Crossref
Crossref
Yoichiro Ogama, Tomoko Mineyama, Asuka Yamamoto, Margaret Woo, Naomi Shimada, Taro Amagasaki & Kazuto Natsume. (2013) A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers. International Journal of Hematology 97:3, pages 351-359.
Crossref
Crossref
Juan Zhou, Yuanxin Ye, Shugen Zeng, Yi Zhou, Zhigang Mao, Xingbo Song, Binwu Ying, Xiaojun Lu, Hong Jiang & Lanlan Wang. (2013) Impact of JAK2 V617F Mutation on Hemogram Variation in Patients with Non-Reactive Elevated Platelet Counts. PLoS ONE 8:2, pages e57856.
Crossref
Crossref
Camilla Nielsen, Henrik S. Birgens, Børge G. Nordestgaard & Stig E. Bojesen. (2012)
Diagnostic value of
JAK
2
V
617
F
somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population
. British Journal of Haematology 160:1, pages 70-79.
Crossref
Crossref
Ana Esther Kerguelén Fuentes, Dolores Hernández-Maraver, Luis Lombardia, Miguel Angel Canales Albendea & Ana Rodriguez de la Rúa. (2012) Impacto clínico de la cuantificación de la carga mutacional de JAK2V617F en pacientes con neoplasias mieloproliferativas crónicas Ph negativas clásicas. Medicina Clínica 139:9, pages 373-378.
Crossref
Crossref
Mutlu Karkucak, Tahsin Yakut, Vildan Ozkocaman, Fahir Ozkalemkas, Ridvan Ali, Murat Bayram, Orhan Gorukmez & Gokhan Ocakoglu. (2012) Evaluation of the JAK2-V617F gene mutation in Turkish patients with essential thrombocythemia and polycythemia vera. Molecular Biology Reports 39:9, pages 8663-8667.
Crossref
Crossref
Rafael Ramos da SilvaBetânia Lucena Domingues HatzlhoferCíntia Gonsalves de Faria MachadoAleide Santos de Melo LimaDulcinéia Martins de AlbuquerqueMagnun Nueldo Nunes dos SantosKleber Yotsumoto FertrinFernando Ferreira CostaAderson da Silva AraújoMarcos Andre Cavalcanti Bezerra. (2012)
JAK2 V617F
Mutation Prevalence in Myeloproliferative Neoplasms in Pernambuco, Brazil
. Genetic Testing and Molecular Biomarkers 16:7, pages 802-805.
Crossref
Crossref
Jill E. Chrencik, Akshay Patny, Iris K. Leung, Brian Korniski, Thomas L. Emmons, Troii Hall, Robin A. Weinberg, Jennifer A. Gormley, Jennifer M. Williams, Jacqueline E. Day, Jeffrey L. Hirsch, James R. Kiefer, Joseph W. Leone, H. David Fischer, Cynthia D. Sommers, Horng-Chih Huang, E.J. Jacobsen, Ruth E. Tenbrink, Alfredo G. Tomasselli & Timothy E. Benson. (2010) Structural and Thermodynamic Characterization of the TYK2 and JAK3 Kinase Domains in Complex with CP-690550 and CMP-6. Journal of Molecular Biology 400:3, pages 413-433.
Crossref
Crossref
Dong Wook JekarlSang Bong HanMyungshin KimJihyang LimEun-Jee OhYonggoo KimHee-Je KimWoo-Sung MinKyungja Han. (2010) JAK2 V617F mutation in myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, unclassifiable, refractory anemia with ring sideroblasts with thrombocytosis, and acute myeloid leukemia. The Korean Journal of Hematology 45:1, pages 46.
Crossref
Crossref